Patent · US Active

Compounds for targeting mutant huntingtin protein and uses thereof

US11389438B2 · kind B2 · utility

0Cited by

4References

9Claims

0Family size

Assignee

CHDI Foundation, Inc. · US

Inventors

Celia Dominguez · Los Angeles, US
Jonathan Bard · New York, US
Matthew Lee · Calabasas, US
Longbin Liu · Thousand Oaks, US
Michael Prime · Woodstock, GB
Samuel Coe · Northampton, GB

Key dates

Filing date	Feb 24, 2020
Grant date	Jul 19, 2022
Priority date	—
Expiry date	Feb 26, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates generally to compounds that simultaneously bind both mutant huntingtin protein (mHTT) and an ubiquitin E3 ligase and their use as therapeutic agents, for example, in treating diseases, such as neurodegenerative disorders caused by aggregation of mHTT.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.